标题：房健民
简介
房健民，男，教授，博士生导师。　
1993年至1997年在加拿大Dalhousie大学生物系攻读生物学博士学位，1997-2000年在美国哈佛大学医学院从事博士后研究。从2000年至2009年，在美国历任Cell Genesys研究公司研究员，高级研究员，新药开发项目负责人；Panorama研究所高级研究员，抗体工程研究部主任。2009年始任同济大学生命科学与技术学院教授，博士生导师。
主要研究抗肿瘤和自身免疫疾病的生物药物开发，肿瘤血管新生的分子调控，干细胞的分化等。发表文章的刊物包括Nature Biotechnology, PNAS, Cancer Research, Molecular Therapy, Developmental Biology等。有多项已授权或公开的发明专利。曾获中国国家科技进步奖二等奖，加拿大Killam 学者奖，加拿大NSERC博士后奖等。
研究方向
1. 单克隆抗体和蛋白质工程新药研究: 单克隆抗体的制备和筛选, 抗体和蛋白质药物的结构优化, 抗体的人源化, 药物的临床前评估, 高表达细胞株的构建; 真核细胞在生物反应器的大规模培养和优化等。
2. 血管新生调控的机理: 肿瘤及视网膜疾病发生过程中血管新生启动的分子机理；MMP对血管新生的调控; 血管内皮生长因子(VEGF)受体的信号传导；VEGF佶抗剂药物研究; Notch 信号途径对血管内皮细胞的调控等.
3. 免疫学： 新型免疫抑制剂对系统性红斑狼疮和类风湿关节炎的作用；治疗性肿瘤疫苗的研究；T细胞负调控因子对肿瘤免疫的作用等。
4. 干细胞生物学：骨骼干细胞的分化及分子调控；机械刺激及细胞间质因子对骨骼干细胞的分化的影响；诱导多能干细胞（iPS细胞)的细胞分化；iPS细胞的基因表达。
5. 基因治疗：治疗性单克隆抗体的基因治疗给药；肿瘤的基因治疗。
主要论文
Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, Vanroey MJ, Allison JP, Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother. 57:1263-70. 2008. 
Fang J, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K. An antibody delivery system for regulated expression of monoclonal antibody at therapeutic level in vivo. Molecular Therapy 15:1153-1159. 2007. 
Harper J, Yan L, Loureiro RM, Wu I, Fang J, D'Amore PA, Moses MA. Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24. Cancer Research. 67:8736-8741. 2007. 
Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K. Stable antibody expression at therapeutic levels using the 2A peptide. Nature Biotechnology 23:584-590. 2005.
Fang J. and Jooss K. Rapid generation of high-level antibodies in vitro and in vivo. Discovery Medicine 5:367-370. 2005.
Marler JJ, Fishman SJ, Kilroy SM, Fang J, Upton J, Mulliken JB, Burrows PE, Zurakowski D, Folkman J, Moses MA. Increased Expression of Urinary Matrix Metalloproteinases Parallels The Extent and Activity of Vascular Anomalies. Pediatrics 116:38-45. 2005. 
Fang J, Yan L, Shing Y, Moses MA. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Research 61:5731-5735. 2001. 
Fang J., Shing Y., Wiederschain D., Yan L., Butterfield C., Jackson G., Harper J., Tamvakopoulos G., Moses M.A. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proceedings of the National Academy of Sciences, USA (PNAS) 97:3884-3889. 2000. 
Fang J. and Hall B.K. N-CAM is not required for initiation of secondary chondrogenesis: The role of N-CAM in skeletal condensation and differentiation. International Journal of Developmental Biology 43: 335-342. 1999. 
Fang J. and Hall B.K. Chondrogenic cell differentiation from membrane bone periostea. Anatomy and Embryology 196: 349-362. 1997. 
Fang J. and Hall B.K. In vitro differentiation potential of the pe
riosteal cells from a membrane bone, the quadratojugal of the embryonic chick. Developmental Biology 180: 701-712. 1996. 
Fang J. and Hall B.K. Differential expression of neural cell adhesion molecule (NCAM) during osteogenesis and secondary chondrogenesis in the embryonic chick. International Journal of Developmental Biology 39: 519-528. 1995.